IPH5201 + durvalumab + standard chemotherapy clinical trials

IPH5201 and Durvalumab in Patients With Resectable Non-Small Cell Lung Cancer (MATISSE)

This study looks at a new combination of medicines, IPH5201 and durvalumab, along with standard chemotherapy, for people with early-stage lung cancer. Doctors want to see if this new treatment, given before and after surgery, is safe and effective in helping to treat the cancer.